Scarica l'app Stockscreener
90.73
1.10%
0.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$89.74
Aprire:
$88.82
Volume 24 ore:
832.74K
Relative Volume:
1.76
Capitalizzazione di mercato:
$4.40B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-20.03
EPS:
-4.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
+0.70%
1M Prestazione:
-4.09%
6M Prestazione:
+20.68%
1 anno Prestazione:
+28.60%
Intervallo 1D:
$87.69
$93.12
Intervallo di 1 settimana:
$87.69
$94.64
Portata 52W:
$64.11
$105.00
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
90.73 | 4.40B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Franklin Resources Inc. Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Barclays PLC Buys 45,509 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Geode Capital Management LLC Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Sleep Apnea Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Treatment Outlook | Axsome Therapeutics/Jazz Pharma, Bioprojet Pharma, Taisho Pharma - Barchart
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 4%Here's What Happened - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Lowered by State Street Corp - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 7.9% in November - MarketBeat
Axsome Therapeutics' SWOT analysis: strong growth, pipeline potential lift stock - Investing.com
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report? - MSN
Captrust Financial Advisors Acquires Shares of 5,722 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,479 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Wellington Management Group LLP Acquires 8,125 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Zacks Research Issues Pessimistic Forecast for AXSM Earnings - MarketBeat
Fmr LLC Has $97.79 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Charles Schwab Investment Management Inc. Buys 12,778 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is RTW Investments LP's 2nd Largest Position - MarketBeat
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HighVista Strategies LLC Sells 20,650 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Smoking Cessation and Nicotine Addiction Market Growth Anticipated by 2034 | Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, expected to boost the market - The Globe and Mail
Smoking Cessation and Nicotine Addiction Market Growth - openPR
PDT Partners LLC Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
9,466 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Fred Alger Management LLC - MarketBeat
Trend Tracker for (AXSM) - Stock Traders Daily
Bellevue Group AG Decreases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Eventide Asset Management LLC Has $74.40 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome: Focus On AXS-12 Targeting Narcolepsy, Just Released Positive Data (NASDAQ:AXSM) - Seeking Alpha
FORA Capital LLC Makes New $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Brokers Reduce Earnings Estimates for AXSM - MarketBeat
Cynosure Group LLC Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Intech Investment Management LLC Makes New $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says - AOL
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria
HC Wainwright Has Bullish Estimate for AXSM FY2024 Earnings - MarketBeat
Axsome's AXS-12 shows efficacy in narcolepsy trial By Investing.com - Investing.com Canada
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy - MSN
Axsome Therapeutics eyes approval after Phase III narcolepsy win - Clinical Trials Arena
Positive Phase III data in narcolepsy from Axsome - The Pharma Letter
Axsome Therapeutics Announces AXS-12 Achieves Primary - GlobeNewswire
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week - Yahoo Finance
Axsome's AXS-12 shows efficacy in narcolepsy trial - Investing.com India
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis - Yahoo Finance
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy - The Manila Times
Loomis Sayles & Co. L P Acquires 29,497 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome's AXS-12 Shows 77% Reduction in Narcolepsy Attacks in Phase 3 Trial Success | AXSM Stock News - StockTitan
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Brokerages - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome shares reiterate Buy rating on strong Q3 results By Investing.com - Investing.com UK
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet? - Simply Wall St
Eagle Asset Management Inc. Lowers Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Saad Mark E | Director |
Sep 11 '24 |
Option Exercise |
3.67 |
11,016 |
40,429 |
21,018 |
| Saad Mark E | Director |
Sep 11 '24 |
Sale |
91.31 |
11,016 |
1,005,871 |
10,002 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):